(Q37172820)

English

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial (English)

1 reference

Europe PubMed Central

18 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jiří Vencovský

object named as

J Vencovsky

12

0 references

Gerd-Rüdiger Burmester

10

object named as

G R Burmester

1 reference

Europe PubMed Central

18 August 2017

author name string

J Smolen

1

1 reference

Europe PubMed Central

18 August 2017

R B Landewé

2

1 reference

Europe PubMed Central

18 August 2017

P Mease

3

1 reference

Europe PubMed Central

18 August 2017

J Brzezicki

4

1 reference

Europe PubMed Central

18 August 2017

D Mason

5

1 reference

Europe PubMed Central

18 August 2017

K Luijtens

6

1 reference

Europe PubMed Central

18 August 2017

R F van Vollenhoven

7

1 reference

Europe PubMed Central

18 August 2017

A Kavanaugh

8

1 reference

Europe PubMed Central

18 August 2017

M Schiff

9

1 reference

Europe PubMed Central

18 August 2017

V Strand

11

1 reference

Europe PubMed Central

18 August 2017

D van der Heijde

13

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

17 November 2008

1 reference

Europe PubMed Central

18 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

18 August 2017

68

1 reference

Europe PubMed Central

18 August 2017

797-804

1 reference

Europe PubMed Central

18 August 2017

6

1 reference

Europe PubMed Central

18 August 2017

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

How to read radiographs according to the Sharp/van der Heijde method.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Role of cytokines in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

6 September 2017

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

14 September 2017

Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

27 June 2018

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

27 June 2018

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

3 September 2018

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

3 September 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674556

3 September 2018

Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time

1 reference

https://pubmed.ncbi.nlm.nih.gov/19015207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19015207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19015207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/19015207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

https://pubmed.ncbi.nlm.nih.gov/19015207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimum important difference between patients with rheumatoid arthritis: the patient's perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/19015207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of targeted anticytokine treatments in heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/19015207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19015207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19015207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19015207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ARD.2008.101659

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37172820&oldid=1692467613"